通化金马(000766) - 2024 Q2 - 季度财报

Financial Performance - The company's operating revenue for the first half of 2024 was ¥649,181,711.75, a decrease of 10.89% compared to ¥728,491,083.33 in the same period last year[21]. - Net profit attributable to shareholders increased by 15.69% to ¥12,468,342.98 from ¥10,776,911.31 year-on-year[21]. - The net profit after deducting non-recurring gains and losses was ¥6,401,376.02, down 16.96% from ¥7,709,212.42 in the previous year[21]. - The net cash flow from operating activities was ¥38,108,424.15, a decrease of 7.28% compared to ¥41,102,119.70 in the same period last year[21]. - Basic and diluted earnings per share both increased by 15.18% to ¥0.0129 from ¥0.0112 year-on-year[21]. - Total revenue for the reporting period was ¥649,181,711.75, a decrease of 10.89% compared to ¥728,491,083.33 in the same period last year[47]. - Operating profit for the first half of 2024 was CNY 13,911,056.79, an increase of 21.8% from CNY 11,424,594.92 in the previous year[148]. - Net profit for the first half of 2024 reached CNY 12,351,414.08, up 20.0% from CNY 10,304,366.03 in the same period of 2023[149]. Assets and Liabilities - Total assets at the end of the reporting period were ¥4,599,572,689.11, an increase of 1.78% from ¥4,519,244,365.23 at the end of the previous year[21]. - The total liabilities increased to CNY 2,269,094,096.74 from CNY 2,201,117,186.94, reflecting a rise of about 3.09%[142]. - Short-term borrowings rose to ¥234,706,111.11, accounting for 5.10% of total assets, an increase from 2.88% last year[54]. - The accounts receivable stood at ¥497,419,598.81, slightly up by 0.18% from ¥496,821,395.71[54]. - The total equity attributable to shareholders increased to CNY 2,330,131,262.54 from CNY 2,317,662,919.56, reflecting a growth of approximately 0.54%[142]. Research and Development - Research and development investment rose by 23.55% to ¥31,003,332.41, reflecting the company's commitment to innovation[45]. - The company has a total of 41 invention patents and 73 utility model patents, indicating a strong focus on intellectual property protection[41]. - Research and development expenses decreased to CNY 18,333,726.34, down 15.0% from CNY 21,717,792.04 year-on-year[148]. Sales and Marketing Strategy - The company employs a "production based on sales" model, ensuring compliance with national GMP regulations and adapting production plans according to market demand[34]. - The sales strategy includes a combination of direct sales and agency models, leveraging academic promotion to enhance product recognition among healthcare professionals[34]. - The company has established a clinical sales division to adapt to industry policy changes and enhance market responsiveness[35]. - The company is focusing on expanding its market presence through competitive management and flexible sales strategies tailored to regional characteristics[35]. Environmental Compliance - The company strictly adheres to national environmental protection laws and local regulations, including the Environmental Protection Law and the Water Pollution Prevention Law[78]. - The wastewater discharge permit for Tonghua Jinma is valid from November 21, 2022, to November 20, 2027[78]. - The average COD concentration for Tonghua Jinma's wastewater is 16.81 mg/L, with a total discharge of 1.14 tons per year[79]. - The company has implemented strict measures to ensure that all emissions are within regulatory limits, with no exceedances reported[79]. - The company is committed to continuous improvement in environmental performance and compliance with evolving regulations[78]. Corporate Governance - The company has not reported any significant environmental or social safety issues in the first half of 2024[82]. - There were no significant lawsuits or arbitration matters reported during the period[100]. - The company did not engage in any major related party transactions during the reporting period[102]. - The company has not conducted any asset or equity acquisitions or sales during the reporting period[103]. - The financial report for the first half of 2024 has not been audited[138]. Shareholder Information - The total share capital of Tonghua Jinma Pharmaceutical Group Co., Ltd. is 96,649.47 million shares as of June 30, 2024[184]. - The largest shareholder, Yu Lanjun, holds 19.66% of the shares, totaling 190,000,000 shares, which are pledged[127]. - The total number of shareholders and their holdings remained stable, with no significant changes reported[125]. - The company has not issued any new securities or listed any new shares during the reporting period[125].